To date, potential biomarkers such as PD-L1 expression, CD8+ T-cell infiltration, DDR gene alterations, tumor mutational burden (TMB) and immune and stromal gene expression signatures have been correlated with immunotherapy response (80, 81). This evidence concerns the gene CD8A and neoplasm.